|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SEPT14 |
Gene summary for SEPT14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SEPT14 | Gene ID | 346288 |
| Gene name | septin 14 | |
| Gene Alias | SEPT14 | |
| Cytomap | 7p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q6ZU15 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 346288 | SEPT14 | S014 | Human | Liver | HCC | 1.67e-14 | 5.20e-01 | 0.2254 |
| 346288 | SEPT14 | S015 | Human | Liver | HCC | 1.66e-05 | 2.56e-01 | 0.2375 |
| 346288 | SEPT14 | S016 | Human | Liver | HCC | 1.56e-15 | 5.17e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Liver | Cyst |  |
| Lung | IAC |  |
| Lung | AIS |  |
| Lung | AAH |  |
| Lung | MIAC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SEPT14 | SNV | Missense_Mutation | c.36N>G | p.Ile12Met | p.I12M | Q6ZU15 | protein_coding | tolerated(0.09) | benign(0.17) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| SEPT14 | SNV | Missense_Mutation | c.409N>C | p.Glu137Gln | p.E137Q | Q6ZU15 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
| SEPT14 | SNV | Missense_Mutation | c.110N>A | p.Cys37Tyr | p.C37Y | Q6ZU15 | protein_coding | deleterious(0) | possibly_damaging(0.61) | TCGA-BH-A1FM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SEPT14 | SNV | Missense_Mutation | c.347N>A | p.Gly116Asp | p.G116D | Q6ZU15 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SEPT14 | insertion | Frame_Shift_Ins | novel | c.377_378insTCTTGAAGGC | p.Gln126HisfsTer8 | p.Q126Hfs*8 | Q6ZU15 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SEPT14 | SNV | Missense_Mutation | novel | c.781G>A | p.Val261Ile | p.V261I | Q6ZU15 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SEPT14 | SNV | Missense_Mutation | c.1191A>C | p.Lys397Asn | p.K397N | Q6ZU15 | protein_coding | deleterious(0.02) | benign(0.423) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| SEPT14 | SNV | Missense_Mutation | c.43G>A | p.Asp15Asn | p.D15N | Q6ZU15 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SEPT14 | SNV | Missense_Mutation | rs78957351 | c.826N>A | p.Glu276Lys | p.E276K | Q6ZU15 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| SEPT14 | SNV | Missense_Mutation | rs761205837 | c.617C>T | p.Thr206Met | p.T206M | Q6ZU15 | protein_coding | deleterious(0.03) | possibly_damaging(0.871) | TCGA-AA-3854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |